Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review.
OBJECTIVE
To describe the features of carcinoembryonic antigen (CEA) that are important for its use in vaccination approaches and review the clinical experience with therapeutic vaccines targeting CEA.


METHODS
A PubMed search was performed on CEA, along with various qualifiers such as cancer vaccines, epitopes, and function. Relevant articles were reviewed.


RESULTS
CEA is a member of the immunoglobulin supergene family and may play a role in tumorigenesis. CEA protein is processed and presented on major histocompatibility complex (MHC) proteins for multiple alleles, including HLA A2, A3, and A24. T lymphocytes from healthy volunteers and cancer patients can recognize the processed epitopes of CEA and can become activated to lyse CEA-expressing tumors. Therapeutic vaccination approaches that have targeted CEA include vaccination with recombinant CEA protein, CEA anti-idiotype antibodies, and dendritic cells pulsed with agonist epitopes of CEA. Humoral responses have predominantly been induced with the first two approaches, whereas CD4 and CD8 responses, disease stabilization, and even objective clinical responses have been seen with the dendritic cell approach. Recently, CEA-poxvirus vectors encoding CEA and costimulatory molecules such as B7.1 have been shown to be safe and to induce increases in the frequency of T-cell precursors that recognize processed epitopes of CEA presented on MHC class 1 molecules. Disease stabilization has been seen in up to 37% of patients treated with these vaccines.


CONCLUSIONS
Tolerance to CEA in patients with cancer can be overcome with several different vaccination approaches, and such vaccinations are safe and immunologically active. Poxvirus-based vaccines can reproducibly generate T-cell responses to CEA and to tumors expressing CEA. Clinical activity has been seen with poxvirus or dendritic cell approaches. Other approaches are also being explored.
Berinstein
Neil L
NL
Aventis Pasteur Ltd, Toronto, Ontario, Canada. neil.berinstein@aventis.com
D000818:Animals; D000917:Antibody Formation; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D002986:Clinical Trials as Topic; D000939:Epitopes; D005822:Genetic Vectors; D006801:Humans; D007111:Immunity, Cellular; D016131:Lymphocyte Subsets / Q000276:immunology; D008285:Major Histocompatibility Complex; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D011212:Poxviridae
D019496:Cancer Vaccines; D002272:Carcinoembryonic Antigen; D000939:Epitopes